Elevation Oncology’s (ELEV) Outperform Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV) in a report released on Friday,RTT News reports. They currently have a $5.00 price target on the stock. William Blair also issued estimates for Elevation Oncology’s Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.21) EPS and Q4 2025 earnings at ($0.24) EPS.

Several other research firms also recently weighed in on ELEV. Stephens reiterated an “overweight” rating and set a $5.00 target price on shares of Elevation Oncology in a research report on Friday. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Elevation Oncology in a research report on Tuesday, January 14th. Finally, JMP Securities reiterated a “market outperform” rating and set a $7.00 target price on shares of Elevation Oncology in a research report on Thursday, December 19th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Elevation Oncology currently has an average rating of “Buy” and an average price target of $6.83.

Elevation Oncology Price Performance

NASDAQ ELEV opened at $0.51 on Friday. The company has a market capitalization of $30.20 million, a PE ratio of -0.62 and a beta of 1.37. The company has a debt-to-equity ratio of 0.45, a quick ratio of 17.77 and a current ratio of 17.77. The business’s fifty day moving average is $0.64 and its 200 day moving average is $0.62. Elevation Oncology has a fifty-two week low of $0.41 and a fifty-two week high of $5.83.

Elevation Oncology (NASDAQ:ELEV) last released its earnings results on Thursday, March 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04. Sell-side analysts predict that Elevation Oncology will post -0.84 earnings per share for the current year.

Hedge Funds Weigh In On Elevation Oncology

Several large investors have recently made changes to their positions in ELEV. Velan Capital Investment Management LP purchased a new position in shares of Elevation Oncology in the fourth quarter valued at about $25,000. Bank of America Corp DE boosted its stake in Elevation Oncology by 42.5% during the fourth quarter. Bank of America Corp DE now owns 56,839 shares of the company’s stock valued at $32,000 after buying an additional 16,962 shares during the last quarter. SG Americas Securities LLC grew its holdings in Elevation Oncology by 33.9% during the 4th quarter. SG Americas Securities LLC now owns 61,467 shares of the company’s stock valued at $35,000 after buying an additional 15,560 shares in the last quarter. Two Sigma Securities LLC bought a new stake in Elevation Oncology in the 4th quarter worth approximately $35,000. Finally, Virtu Financial LLC purchased a new stake in shares of Elevation Oncology during the 4th quarter worth approximately $36,000. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.